knowledge -WSS

knowledge

author：explore 2025-09-27 19:38:15 - browse：69

Stoke Therapeutics is still seeking an effective dose for an experimental drug to treat a severe form of childhood epilepsy, following the release of updated data Tuesday that showed disappointing reductions in convulsive seizure activity.

In the latest look at an ongoing mid-stage study, three monthly injections of the Stoke drug, called STK-001, given at a 45-mg dose, resulted in a median 18% reduction in convulsive seizure activity, compared to baseline.

The new analysis was conducted on 16 children diagnosed with a rare form of epilepsy called Dravet syndrome. Last November, in six patients, the drug showed a median 55% reduction in seizure activity.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Ending racial health disparities hinges on penalties, political will

hotspot

explore

WSS

DeSantis talks Trump, trans issues and 'what wokeness is'

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Readers respond to H5N1 and livestock movements, and more

Stanford president's case begs question: Who takes blame?

Winning ticket for $1 billion Powerball jackpot sold in California

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

hotspot

knowledge

entertainment

Psychedelics group wrestles with new pharma identity

Addiction experts warn against a second 'war on drugs'

In Memoriam: Notable people who died in 2023

Solving academic medical centers' existential crisis

In Memoriam: Notable people who died in 2023

NVIDIA and Google execs on the future of AI and drug discovery

New air purifier tech could be key to improving indoor air quality

Awakening the world to the whoosh: A patient's crusade

DIEP, the 'gold standard' of breast reconstruction, is under threat

Readers respond to H5N1 and livestock movements, and more

explore

Stanford president's case begs question: Who takes blame?

Why Congress must ban federal programs from using QALYs

Glen Campbell's doctor discusses his public struggle with Alzheimer's

It's time to retire 'poor historian' from clinicians' vocabularies

Data integrity in scientific journals requires "effort" by publishers, institutions

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

explore

hotspot

explore

Wikipedia